Halozyme (HALO) Q4 2025 earnings review
Record Top-Line Masked by Accounting Noise
Halozyme delivered a massive revenue beat with 52% YoY growth in Q4, driven by its royalty engine (DARZALEX, Phesgo, VYVGART). However, the headline Net Income collapsed to a $141.6M loss due to a $285M one-time IPR&D charge related to the Surf Bio acquisition. Ignoring this accounting optics, the core business is accelerating. Management reiterated bullish FY26 guidance, projecting EBITDA to nearly double to ~$1.16B as the M&A costs normalize and royalty streams compound.
🐂 Bull Case
Royalty revenue grew 51% YoY in Q4, accelerating from prior quarters. The 'Big Three' (DARZALEX SC, Phesgo, VYVGART Hytrulo) continue to gain global market share, with FY26 royalty revenue guided to grow another 30-35%.
The acquisitions of Elektrofi and Surf Bio are closed, expanding the moat into high-concentration biologics and extending patent horizons into the mid-2040s. The pain (cash outlay/charges) is taken in 2025; the gain starts in 2026.
🐻 Bear Case
Cash and equivalents plummeted from $596M a year ago to $145M due to M&A and buybacks. While cash flow is strong, the liquidity cushion has thinned significantly.
The infringement battle with Merck (Keytruda SC) and ongoing validity challenges create a layer of uncertainty. While management is confident, legal outcomes are binary and risky.
⚖️ Verdict: 🟢
Bullish. Look past the ugly GAAP Net Loss. The core royalty business is growing at 50%+, and the FY26 guidance implies massive operating leverage. The acquisitions are strategic bets that sacrifice current cash for decades of future dominance.
Key Themes
GAAP Profitability Shock
Q4 Net Income swung from a $137M profit last year to a $141.6M loss. This was entirely driven by a $284.9M 'acquired IPR&D expense' from the Surf Bio deal. While non-cash and one-time, it complicates the optical quality of earnings and dragged full-year GAAP EPS down to $2.56 (vs $3.43 in FY24).
Royalty Growth Acceleration
Accelerating. Royalty revenue grew 51% YoY in Q4 to $258M, outpacing the 39% growth seen in Q1. The conversion of IV therapies to Subcutaneous (SC) continues rapidly. Management projects royalties to exceed $1 billion in 2026, a year earlier than previously expected.
Product Sales Spike
Product sales (API) surged 55% YoY in Q4 to $122.7M. This indicates partners are stocking up on rHuPH20 enzyme, a leading indicator for future commercial demand. However, this line item carries lower margins than royalties, slightly diluting gross margin mix.
Cash Position Drawdown
Reversing. Cash and equivalents fell to $145.4M from $596.1M a year ago. The company spent heavily on the Elektrofi/Surf Bio acquisitions and share repurchases. While operating cash flow remains positive, the fortress balance sheet has been leveraged to fund growth, reducing near-term flexibility.
Patent Wars: Merck vs. Halozyme
The release explicitly mentions ongoing litigation costs ($8.1M in Q4) regarding the Merck Keytruda SC dispute and a preliminary injunction in Germany. This remains a high-stakes binary event: a win secures royalties on the world's biggest drug; a loss limits the upside.
Other KPIs
Decelerating drastically from $195.8M in 24Q4 *if* taken at face value. However, this includes the $284.9M IPR&D charge. Excluding this charge, EBITDA would be ~$306M, representing ~56% YoY growth. The underlying profitability is intact.
Reversing. Down from $3.43 in FY24. The decline is strictly due to the Q4 acquisition charges ($2.30 per share impact). Without the deal costs, EPS growth would have tracked with revenue.
Accelerating. Up 87% YoY, growing faster than the 52% revenue growth. Attributed to higher product sales volume (lower margin) and labor allocation initiatives.
Guidance
Decelerating. Implies 22-30% YoY growth, compared to FY25's 38% growth. However, this remains a very high growth rate for a company of this scale, driven by royalty compounding.
Decelerating slightly. Implies 30-35% growth vs 52% in FY25. This reflects the law of large numbers as the base expands, but crossing the $1B threshold is a major milestone.
Accelerating. Represents 71-83% growth over FY25. This massive jump reflects the normalization of M&A costs and the extreme operating leverage of the royalty model.
Accelerating. Implies 87-99% growth over FY25 ($4.15). Management notes this includes ~$60M in new investments for Hypercon/Surf Bio, showing the core business can fund R&D while doubling earnings.
Key Questions
Cash Rebuild Timeline
With cash balances down to ~$145M and significant acquisition integration costs ahead ($60M guided), how quickly does management expect to rebuild the balance sheet to support future buybacks?
Merck Litigation Update
With litigation costs rising and a preliminary injunction mentioned in Germany, what is the timeline for the next major court decision, and is there any settlement discussion active?
Hypercon/Surf Bio Commercialization
With the acquisitions closed, when will we see the first material revenue contribution from these high-concentration technologies, and are there signed partners waiting in the wings?